article thumbnail

A Bold Goal: Reshoring 25% of Small Molecule API to the U.S. in 5 Years – APIIC’s Report to The White House

FDA Law Blog: Biosimilars

is identified as “Improving Supply Chains for Critical Drugs,” and states: “ In 5 years, deploy broad synthetic biology and biomanufacturing capabilities to produce at least 25% of all active pharmaceutical ingredients (APIs) for small molecule drugs ” (emphasis added). The first goal under Theme 1—Goal 1.1—is

article thumbnail

Demystifying the ICH M10 Bioanalytical Method Validation Guidelines

Conversations in Drug Development Trends

Stability Tests: For small molecule, only -20°C stability testing is required, while large molecule need both -20°C and -70°C tests if samples are intended for storage at these temperatures. Quality Control Batches : These batches are utilized to ensure the assay’s accuracy when measuring various study samples.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Listicle: Maximising outsourcing models beyond time and cost

Drug Discovery World

This white paper expands on three key factors – cost, time, and innovation – and illustrates how integrating these factors will minimise the challenges and ensure success in outsourcing drug discovery. protein-protein or small molecule-target interactions). Compound libraries: Small molecules, large roles.

article thumbnail

Analysis Life Sciences Thank You CDER’s Office of Pharmaceutical Quality to reorganize, citing need to address ‘pain points’

Agency IQ

Read AgencyIQ’s analysis of FDA’s QMM White Paper here.] What the offices will focus on: OPQA I and II are set to focus on small-molecule product assessments. OPQA III will “focus on drug substance assessment for both large and small molecule products.”

article thumbnail

Top 10 Drug Discovery Trends at the Top 20 Pharma

PerkinElmer

A PerkinElmer White Paper offers a detailed look at the findings. Small molecules are making a comeback. For the minority of companies working with large molecules and biologics, most said they were in a phase of clinical research. Top 10 trends in pre-clinical drug discovery at top 20 Pharma 1.

article thumbnail

Codon Digest: Vaccine Printer Go Brrrrr!

Codon

Read An automated platform to make riboswitches (RNA strands that bind to small molecules and then quickly switch their structure) that can sense specific proteins. Note: I’m employed by the company and a co-author on the paper.) Cell Systems. Nature Communications. Read That’s it for today! See you next week.

Vaccine 52
article thumbnail

Codon Digest: Vaccine Printer Go Brrrrr!

Codon

Read An automated platform to make riboswitches (RNA strands that bind to small molecules and then quickly switch their structure) that can sense specific proteins. Note: I’m employed by the company and a co-author on the paper.) Cell Systems. Nature Communications. Read That’s it for today! See you next week.

Vaccine 52